Gewählte Publikation:
Worel, N; Greinix, H; Ackermann, J; Kaufmann, H; Urbauer, E; Höcker, P; Gisslinger, H; Lechner, K; Kalhs, P; Drach, J.
Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma.
Ann Hematol. 2001; 80(6):345-348
Doi: 10.1007/s002770100296
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Interphase cytogenetic analysis of chromosome 13q14 was performed in 28 patients with multiple myeloma (MM) receiving high-dose therapy followed by autologous (n=24) or allogeneic (n=4) stem cell support. Eleven (39%) patients were found to have a deletion of chromosome 13q14. Response rates to high-dose therapy were independent of the chromosome 13 status, but patients with a deletion of 13q14 had a significantly shorter progression-free (p=0.001) and overall survival (p=0.012) than patients with normal chromosome 13q14. Our results indicate that high-dose therapy appears promising in patients with normal chromosome 13, whereas in patients with a deletion of 13q14 innovative therapeutic concepts are warranted.
- Find related publications in this database (using NLM MeSH Indexing)
-
Actuarial Analysis -
-
Adult -
-
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
-
Chromosomes, Human, Pair 13 - genetics
-
Disease-Free Survival -
-
Female -
-
Gene Deletion -
-
Hematopoietic Stem Cell Transplantation -
-
Humans -
-
In Situ Hybridization, Fluorescence -
-
Male -
-
Middle Aged -
-
Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - genetics
-
Prognosis -
-
Retrospective Studies -
-
Survival Rate -
-
Treatment Outcome -
- Find related publications in this database (Keywords)
-
high-dose therapy in multiple myeloma
-
FISH analysis
-
deletion of chromosome 13q14